Treatment of erectile dysfunction following transvesical prostatectomy
- Authors: Motin PI1, Andrjuhin MI2, Pulbere SA1, Alekseev OJ.1, Agaev NK1
-
Affiliations:
- City Hospital № 29
- PFU
- Issue: No 4 (2015)
- Pages: 96-101
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/281902
- ID: 281902
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
This study examines the efficacy and safety of phosphodiesterase type 5 (PDE-5) inhibitors in treating erectile dysfunction after transvesical prostatectomy. The study involved 63 men aged 55 to 68 years, divided into two groups - 29 and 34 patients, respectively. Patients in group 1 received 50 mg of sildenafil citrate (Ereksezil®) on a daily basis, in group 2 - 100 mg of sildenafil citrate (Ereksezil®) on demand. Postoperative visits were scheduled at the stage of screening, then after a month of treatment and on day 14 after treatment completion (3 visits altogether). Changes of patients' complaints according to IIEF-15 questionnaire showed a significant improvement in erectile function and its components of sexual life satisfaction in both groups of patients, but more significantly with regular medication intake, which has a positive impact on patients' quality of life. At the same time, treatment by PDE-5 inhibitors did not affect the maximum urinary flow rate and residual urine volume. Given the high incidence of the postoperative erectile dysfunction, postoperative administration of PDE-5 inhibitors is relevant and promising.
About the authors
P I Motin
City Hospital № 29City Hospital № 29
M I Andrjuhin
PFUPFU
S A Pulbere
City Hospital № 29City Hospital № 29
O Ju Alekseev
City Hospital № 29City Hospital № 29
N K Agaev
City Hospital № 29City Hospital № 29
References
- Descazeaud A., de La Taille A., Giuliano F., Desgrandchamps F., Doridot G. Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prog. Urol. 2015;25(3):115 - 127.
- Kovac J.R. A critical analysis of the 2014 CUA guidelines for erectile dysfunction: Is there more that can be done? Can Urol. Assoc. J. 2015;9(1-2):30-31.
- Сергиенко Н.Ф., Васильченко М.И., Кудряшов О.И., Бегаев А.И., Щекочихин А.В., Шершнев С.П., Рейнюк О.Л., Лотоцкий М.М. Преимущества и отличительные особенности экстрауретральной аденомэктомии перед эндоуретральной, трансуретральной и позадилобковой. Тезисы Всероссийской юбилейной научно-практической конференции, посвященной 200-летию со дня рождения Н.Н. Пирогова. М., 2010. С.184-185.
- Pavone C., Abbadessa D., Scaduto G., Caruana G., Scalici Gesolfo C, Fontana D., Vaccarella L. Sexual dysfunctions after transurethral resection of the prostate (TURP): evidence from a retrospective study on 264 patients. Arch. Ital. Urol. Androl. 2015 ;87(1):8-13.
- Ефремов Е.А. Эректильная дисфункция как полиэтиологический синдром. Дисс. докт. мед. наук. М., 2011. 6.
- PietrzykB., Olszanecka-GlinianowiczM., OwczarekA., GabryelewiczT., Almgren-Rachtan A., Prajsner A., Chudek J. Depressive symptoms in patients diagnosed with benign prostatic hyperplasia. Int. Urol. Nephrol. 2015;47(3):431 -440.
- Chen L., Staubli S.E., Schneider M.P., Kessels A.G., Ivic S., Bach- mann L.M., Kessler T.M. Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: A Trade-off Network Metaanalysis. Eur. Urol. 2015;26.
- Kim E., Seftel A., Goldfischer E., Baygani S., Burns P. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr. Med. Res. Opin. 2015;31(2):379-389.
Supplementary files
